Drug Trial Radar · NCT00657904
Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Jun 6, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,618
Actual
Start
Aug 1995
Primary completion
Jul 2008
Study completion Aug 2008
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 14, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to study the effect - in terms of time to progression and overall survival - of 2 years of adjuvant bicalutamide 150mg monotherapy, versus placebo, in subjects with histologically or cytologically confirmed non-metastatic adenocarcinoma of the prostate gland.
Conditions
- Non-metastatic Prostate Cancer
Interventions
BicalutamideDrug
150mg daily
PlaceboDrug
once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to clinical progressionTime frame: Throughout study period
- Overall patient survivalTime frame: Throughout study period
Locations
85 sites in 2 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Mobile, Alabama
Research Site
Scottsdale, Arizona
Research Site
Tucson, Arizona
Research Site
Berkeley, California
Research Site
Laguna Woods, California
Research Site
Newport Beach, California
Research Site
San Diego, California
Research Site
San Francisco, California
Research Site
Santa Monica, California
Research Site
Thousand Oaks, California
Research Site
Torrance, California
Research Site
Van Nuys, California
Research Site
Denver, Colorado
Research Site
Middlebury, Connecticut
Research Site
New Haven, Connecticut
Research Site
Washington D.C., District of Columbia
Research Site
Aventura, Florida
Research Site
Bay Pines, Florida
Research Site
Boca Raton, Florida
Research Site
Daytona Beach, Florida
Research Site
Fort Myers, Florida
Research Site
Gainesville, Florida
Research Site
Miami, Florida
Research Site
Ocala, Florida
Research Site
Saint Augustine, Florida
Research Site
Atlanta, Georgia
Research Site
Chicago, Illinois
Research Site
Fort Wayne, Indiana
Research Site
Greenwood, Indiana
Research Site
Iowa City, Iowa
Research Site
Kansas City, Kansas
Research Site
Louisville, Kentucky
Research Site
Shreveport, Louisiana
Research Site
Greenbelt, Maryland
Research Site
Rockville, Maryland
Research Site
Burlington, Massachusetts
Research Site
Newtown, Massachusetts
Research Site
Ann Arbor, Michigan
Research Site
Detroit, Michigan
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.